ImpriMed Raises $10 Million in Series A2 Funding
ImpriMed, a company that leverages live-cell testing and artificial intelligence to predict drug responses in veterinary oncology, human blood cancers, and pharmaceutical drug development, has announced the successful closure of its Series A2 funding round. The Seoul-based company has raised $10 million, with LB Investment leading the round. Other participants in this funding round include NAVER D2SF, Samsung Securities, Alois Ventures, BonAngels, and Han River Partners.
Leadership and Vision
The company was co-founded by Jamin Koo, who serves as the CTO, and Sungwon Lim, who is the CEO. Minh B. plays a critical role in customer success and serves as the executive assistant to the CEO. The leadership team is focused on expanding the company's capabilities in AI-driven drug response prediction.
Strategic Use of Funds
While specific details on the use of the new funds were not disclosed, it is expected that the investment will support ImpriMed in advancing its AI technologies and expanding its reach in both the veterinary and human healthcare markets.
About the Investors
LB Investment, the lead investor in this round, is known for backing innovative companies in the technology and healthcare sectors. The participation of NAVER D2SF, Samsung Securities, Alois Ventures, BonAngels, and Han River Partners highlights the strong interest and confidence in ImpriMed's unique approach to drug response prediction.
With this new injection of capital, ImpriMed aims to continue its growth trajectory and further its mission to improve healthcare outcomes through innovative AI solutions.